Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version
Two-year data on the oral multiple sclerosis drug show sustained efficacy, and potential benefits of switching from interferon-1a, Novartis says.
Two-year data on the oral multiple sclerosis drug show sustained efficacy, and potential benefits of switching from interferon-1a, Novartis says.